These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1105 related articles for article (PubMed ID: 440203)

  • 1. The effect of methanol extraction residue of BCG on the cellular immune response in patients with malignant melanoma.
    Bartal A; Cohen Y; Mekori T; Haasz R; Robinson E
    Med Pediatr Oncol; 1979; 6(1):1-10. PubMed ID: 440203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of lung cancer by radiotherapy, chemotherapy, and methanol extraction residue of BCG (MER): clinical and immunological studies.
    Robinson E; Bartal A; Cohen Y; Haasz R; Mekori T
    Cancer; 1977 Sep; 40(3):1052-9. PubMed ID: 902232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intralesional injection of the methanol extraction residue of Bacillus Calmette-Guerin (MER) into cutaneous metastases of malignant melanoma.
    Krown SE; Hilal EY; Pinsky CM; Hirshaut Y; Wanebo HJ; Hansen JA; Huvos AG; Oettgen HF
    Cancer; 1978 Dec; 42(6):2648-60. PubMed ID: 728866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A preliminary report on the effects of methanol extraction residue of BCG (MER) on cancer patients.
    Robinson E; Bartal A; Cohen Y; Haasz R
    Br J Cancer; 1975 Jul; 32(1):1-4. PubMed ID: 1100088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
    Lieberman R; Wybran J; Epstein W
    Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical studies of methanol extraction residue fraction of Bacillus Calmette-Guérin as an immunostimulant in patients with advanced cancer.
    Moertel CG; Ritts RE; Schutt AJ; Hahn RG
    Cancer Res; 1975 Nov; 35(11 Pt 1):3075-83. PubMed ID: 1102082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.
    Cohen MH; Jessup JM; Felix EL; Weese JL; Herberman RB
    Cancer; 1978 Jun; 41(6):2456-63. PubMed ID: 657108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral administration of the methanol extraction residue of BCG (MER/BCG): a phase I study in non-oat cell lung cancer patients.
    Bartal AH; Mordohovich D; Lichtig C; Mekori T; Robinson E
    Int J Immunopharmacol; 1983; 5(4):329-34. PubMed ID: 6629593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined-modality treatment of inoperable lung cancer (i.v. immunotherapy, chemotherapy, and radiotherapy).
    Robinson E; Haim N; Segal R; Veseley Z; Mekori T
    Cancer Treat Rep; 1985 Mar; 69(3):251-8. PubMed ID: 2983892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intralesional immune therapy: methanol extraction residue of BCG or purified protein derivative.
    Lokich JJ; Garnick MB; Legg M
    Oncology; 1979; 36(5):236-41. PubMed ID: 481845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781).
    Henz BM; Macher E; Bröcker EB; Suciu S; Steerenberg PA; Jung E; Rümke P
    Dermatology; 1996; 193(2):105-9. PubMed ID: 8884144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunotherapy of malignant melanoma (active specific and non-specific immune stimulation) (author's transl)].
    Kokoschka EM; Micksche M
    Wien Klin Wochenschr; 1976 Nov; 88(21):690-6. PubMed ID: 1007279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MER-BCG (NSC-143769): immunogenicity and toxicity of single and repeated intradermal injections in dogs.
    Gray JH; Esber HJ; Fleischman RW; Schaeppi UH; McCracken D; Bogden AE
    J Immunopharmacol; 1979; 1(3):377-98. PubMed ID: 553113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro induction of cell-mediated immunity to murine leukemia cells. III. Effect of methanol extraction residue fraction of BCG on the generation of cytotoxic lymphocytes against leukemia.
    Kedar E; Nahas F; Unger E; Weiss DW
    J Natl Cancer Inst; 1978 May; 60(5):1097-106. PubMed ID: 147948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granuloma formation in patients after injection of methanol extraction residue (MER-GCG).
    Bartal A; Kerner H; Cohen Y; Robinson E
    J Clin Pathol; 1977 Dec; 30(12):1149-53. PubMed ID: 604361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A preliminary study of intravenous methanol extraction residue of BCG in treatment of advanced cancer.
    Robinson E; Bartal A; Honigman J; Cohen Y
    Br J Cancer; 1977 Sep; 36(3):341-6. PubMed ID: 336070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Granulomatous lymphangitis. A complication of intralymphatic immunotherapy with methanol extraction residue of BCG (MER).
    Kirkwood JM; Ariyan S; Nordlund JJ; Forget BM
    Cancer; 1982 Oct; 50(7):1299-303. PubMed ID: 7104973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active specific and active non-specific immunotherapy in patients with malignant melanoma.
    Kokoschka EM; Cerni C; Micksche M
    Oncology; 1977; 34(5):229-33. PubMed ID: 917456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of systemic BCG therapy in advanced melanoma.
    El-Domeiri AA; Nika B; Hsia WC; Crispen R; Sabet TY; Gupta TK
    Arch Surg; 1977 Mar; 112(3):257-9. PubMed ID: 843215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of oral BCG in the treatment or metastatic malignant melanoma.
    Pritchard KI; Cowan DH; Baker MA; Osoba D; Phillips RA; Clark DA
    Med Pediatr Oncol; 1976; 2(2):173-81. PubMed ID: 785199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.